Is Guardion Health Sciences, Inc. overvalued or undervalued?

As of 5 October 2023, Guardion Health Sciences, Inc. has moved from fair to attractive in its grade change. The company is currently undervalued based on its financial metrics. Key ratios include a Price-to-Earnings (P/E) ratio of 15.2, a Price-to-Book (P/B) ratio of 1.8, and a Return on Equity (ROE) of 12%.
In comparison to its peers, such as Herbalife Nutrition Ltd. with a P/E of 18.5 and Amgen Inc. at a P/E of 14.0, Guardion appears to be trading at a discount. Additionally, the company's recent stock performance has outpaced the Sensex, further reinforcing its undervaluation narrative.